5/29/2020 8:17:35 AM
TG Therapeutics Announces Final Results Of GENUINE Phase 3 Study Evaluating Ublituximab Plus Ibrutinib
5/15/2020 12:43:28 AM
TG Therapeutics Prices Underwritten Public Offering Of 8.5 Mln Shares At $18/Shr
3/3/2020 7:14:52 AM
TG Therapeutics Q4 Net Loss $39.6 Mln Vs Loss $53.9 Mln Last Year
1/16/2020 7:36:44 AM
TG Therapeutics Initiates Rolling Submission Of NDA To FDA For Umbralisib
9/12/2019 7:35:41 AM
TG Therapeutics Presents Data For Ublituximab At The 35th Annual Congress Of ECTRIMS
6/17/2019 7:50:18 AM
TG Therapeutics Announces Presentation Of Preclinical Data For TG-1801
6/17/2019 7:38:39 AM
TG Therapeutics Presents Preclinical Data For TG-1801 At EHA
6/11/2019 7:59:55 AM
TG Therapeutics Confirms Registration Path For Umbralisib Following FDA Meeting
2/26/2019 7:45:14 AM
TG Therapeutics Begins Phase I First-in-Human Clinical Trial Of TG-1801
1/22/2019 7:32:14 AM
TG Therapeutics Receives Breakthrough Therapy Designation From TFDA For Umbralisib For Marginal Zone Lymphoma
12/4/2018 7:34:02 AM
TG Announces Data From Triple Combination Of Ublituximab, Umbralisib, Bendamustine In Patients With DLBCL And FL
12/3/2018 7:49:07 AM
TG Announces Oral Presentation Of Follow-Up Data From Triple Combination Of Ublituximab, Umbralisib, And Pembrolizumab
11/9/2018 7:33:53 AM
TG Therapeutics Q3 Net Loss $34.0 Mln Vs Net Loss $31.5 Mln Last Year
9/26/2018 8:48:41 AM
Jefferies Is Cutting TG Therapeutics Inc. (TGTX) FY20 Estimate To -2.35 From -1.69